Expansion of a Direct-to-Patient Telemedicine Abortion Service in the United States and Experience during the COVID-19 Pandemic

A new Gynuity article including study data on over 1300 U.S. participants confirms that medical abortion using telemedicine and mail is safe, effective, and acceptable. This study provides further evidence that there is no medical reason for mifepristone to be dispensed in clinics as required by the Food and Drug Administration. In some cases, participants did not need to visit any facilities to obtain the service, which was critical to protecting patient safety during the COVID-19 pandemic. Telemedicine abortion has the potential to greatly improve access to abortion care in the U.S. In our TelAbortion study, 60% of participants lived 50 miles or more from their study site, and 36% lived 150 miles or farther.

Access the abstract.